329 related articles for article (PubMed ID: 15616150)
1. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1.
Chen C; Mireles RJ; Campbell SD; Lin J; Mills JB; Xu JJ; Smolarek TA
Drug Metab Dispos; 2005 Apr; 33(4):537-46. PubMed ID: 15616150
[TBL] [Abstract][Full Text] [Related]
2. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein.
Matsushima S; Maeda K; Kondo C; Hirano M; Sasaki M; Suzuki H; Sugiyama Y
J Pharmacol Exp Ther; 2005 Sep; 314(3):1059-67. PubMed ID: 15901800
[TBL] [Abstract][Full Text] [Related]
3. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.
Yamazaki M; Li B; Louie SW; Pudvah NT; Stocco R; Wong W; Abramovitz M; Demartis A; Laufer R; Hochman JH; Prueksaritanont T; Lin JH
Xenobiotica; 2005 Jul; 35(7):737-53. PubMed ID: 16316932
[TBL] [Abstract][Full Text] [Related]
4. P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice.
Chen C; Lin J; Smolarek T; Tremaine L
Drug Metab Dispos; 2007 Oct; 35(10):1725-9. PubMed ID: 17640956
[TBL] [Abstract][Full Text] [Related]
5. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
[TBL] [Abstract][Full Text] [Related]
6. Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells.
Yamasaki D; Nakamura T; Okamura N; Kokudai M; Inui N; Takeuchi K; Watanabe H; Hirai M; Okumura K; Sakaeda T
Eur J Pharm Sci; 2009 May; 37(2):126-32. PubMed ID: 19429419
[TBL] [Abstract][Full Text] [Related]
7. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
Higgins JW; Bao JQ; Ke AB; Manro JR; Fallon JK; Smith PC; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2014 Jan; 42(1):182-92. PubMed ID: 24194513
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Neuvonen PJ; Backman JT; Niemi M
Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
[TBL] [Abstract][Full Text] [Related]
9. Vectorial transport of enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in rat and human livers.
Liu L; Cui Y; Chung AY; Shitara Y; Sugiyama Y; Keppler D; Pang KS
J Pharmacol Exp Ther; 2006 Jul; 318(1):395-402. PubMed ID: 16627748
[TBL] [Abstract][Full Text] [Related]
10. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans.
Yamashiro W; Maeda K; Hirouchi M; Adachi Y; Hu Z; Sugiyama Y
Drug Metab Dispos; 2006 Jul; 34(7):1247-54. PubMed ID: 16624871
[TBL] [Abstract][Full Text] [Related]
11. HMG-CoA reductase inhibitors and P-glycoprotein modulation.
Bogman K; Peyer AK; Török M; Küsters E; Drewe J
Br J Pharmacol; 2001 Mar; 132(6):1183-92. PubMed ID: 11250868
[TBL] [Abstract][Full Text] [Related]
12. Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
Knauer MJ; Urquhart BL; Meyer zu Schwabedissen HE; Schwarz UI; Lemke CJ; Leake BF; Kim RB; Tirona RG
Circ Res; 2010 Feb; 106(2):297-306. PubMed ID: 19940267
[TBL] [Abstract][Full Text] [Related]
13. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Wu X; Whitfield LR; Stewart BH
Pharm Res; 2000 Feb; 17(2):209-15. PubMed ID: 10751037
[TBL] [Abstract][Full Text] [Related]
14. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors.
Choi MK; Shin HJ; Choi YL; Deng JW; Shin JG; Song IS
Xenobiotica; 2011 Jan; 41(1):24-34. PubMed ID: 20946088
[TBL] [Abstract][Full Text] [Related]
15. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2).
Sasaki M; Suzuki H; Ito K; Abe T; Sugiyama Y
J Biol Chem; 2002 Feb; 277(8):6497-503. PubMed ID: 11748225
[TBL] [Abstract][Full Text] [Related]
16. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
17. The effect of the newly developed angiotensin receptor II antagonist fimasartan on the pharmacokinetics of atorvastatin in relation to OATP1B1 in healthy male volunteers.
Shin KH; Kim TE; Kim SE; Lee MG; Song IS; Yoon SH; Cho JY; Jang IJ; Shin SG; Yu KS
J Cardiovasc Pharmacol; 2011 Nov; 58(5):492-9. PubMed ID: 21765368
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.
Ieiri I; Higuchi S; Sugiyama Y
Expert Opin Drug Metab Toxicol; 2009 Jul; 5(7):703-29. PubMed ID: 19442037
[TBL] [Abstract][Full Text] [Related]
19. Membrane transport of camptothecin: facilitation by human P-glycoprotein (ABCB1) and multidrug resistance protein 2 (ABCC2).
Lalloo AK; Luo FR; Guo A; Paranjpe PV; Lee SH; Vyas V; Rubin E; Sinko PJ
BMC Med; 2004 May; 2():16. PubMed ID: 15125776
[TBL] [Abstract][Full Text] [Related]
20. Lactonization is the critical first step in the disposition of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor atorvastatin.
Jacobsen W; Kuhn B; Soldner A; Kirchner G; Sewing KF; Kollman PA; Benet LZ; Christians U
Drug Metab Dispos; 2000 Nov; 28(11):1369-78. PubMed ID: 11038166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
